Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Basit Öğe Kaydı
dc.authoridChan, Stephen Lam/0000-0001-8998-5480
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridKim, Stefano/0000-0003-2851-7119
dc.authorwosidChan, Stephen Lam/F-9149-2011
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorChan, S. L.
dc.contributor.authorMiksad, R.
dc.contributor.authorCicin, I.
dc.contributor.authorChen, Y.
dc.contributor.authorKlumpen, H. J.
dc.contributor.authorKim, S.
dc.contributor.authorLin, Z. Z.
dc.date.accessioned2024-06-12T11:24:06Z
dc.date.available2024-06-12T11:24:06Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.descriptionEuropean-Society-for-Medical-Oncology (ESMO) Asia Congress -- NOV 22-24, 2019 -- Singapore, SINGAPOREen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncol,Japanese Soc Med Oncolen_US
dc.description.sponsorshipExelixisen_US
dc.description.sponsorshipExelixis.en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26793
dc.identifier.volume30en_US
dc.identifier.wosWOS:000503487700124en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofAnnals Of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleOutcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu